Inhibrx Biosciences Inc (INBX) Net earnings per share growth forecast for next year

Corporate company logo of Inhibrx Biosciences (INBX)

The expected annual EPS growth rate for the coming year reflects the forecast dynamics for Inhibrx Biosciences (INBX), where 8.40 represents the current metric level. Inhibrx Biosciences develops therapeutic proteins to combat cancer, aiming for long-term market dominance. The development of advanced antibodies enables the company to secure lucrative contracts with pharma behemoths. The current strategy relies on multi-specific drugs and the support of strategic partners.

Inhibrx Biosciences Inc (INBX): Net earnings per share growth forecast for next year from 07/04/2022 to 11/16/2026

Summary analytical data breakdowns for Inhibrx Biosciences Inc (INBX)

- share price and consensus valuation forecast:
Fundamental company analysis:Inhibrx Biosciences
Finished products of Inhibrx

This indicator reflects the expert community's consensus forecast for earnings per share growth rates in the next period. Investors utilize this metric to assess business scalability potential and the sustainability of cash flows. By analyzing EPS growth prospects for the next fiscal year, one can evaluate the market's level of confidence in the scientific assets of Inhibrx Biosciences (INBX). A stable trajectory of the curve confirms institutional support for the company's therapeutic potential.

Competitor analysis for Inhibrx Biosciences

INCY (incyte.com) - Earnings growth forecast for next year|Expected net earnings per share growth next year hutch-med.com HCM|Net earnings per share growth forecast for next year Nuvation Corp (NUVB)|DAWN - Expected net earnings per share growth next year|Net earnings per share growth forecast for next year Monopar Pharma MNPR|I-Mab - Net earnings per share growth forecast for next year|FENC - Net earnings per share growth forecast for next year|Expected net earnings per share growth next year herontx.com|NVCT: Earnings growth forecast for next year|Net earnings per one share growth forecast for next year Coherus CHRS|Expected earnings per share growth for next year CRBP|Expected net earnings per share growth next year Cardiff Oncology CRDF|Expected earnings per share growth for next year BYSI (BeyondSpring Inc.)|BCAB (BioAtla Corp) - Expected earnings per share trend next year|Lixte Biotechnology - Expected earnings per share growth for next year|Projected earnings per share increase next year CTXR (Citius Pharma)|Cellectar - Earnings growth forecast for next year|Expected earnings per share trend next year BLRX (BioLineRx Corp)|CANF: Earnings growth forecast for next year|Expected net earnings per share growth next year Aprea (APRE)|Net earnings per share growth forecast for next year kaziatherapeutics.com|SLXN: Expected earnings per share trend next year|Earnings growth forecast for next year NCNA|Earnings growth forecast for next year Chimerix Inc (CMRX)|Net earnings per share growth forecast for next year Cyclacel Pharmaceuticals Inc. CYCC|GTHX (g1therapeutics.com) - Net earnings per share change forecast for next year|KRON: Expected earnings per share growth for next year|Expected net earnings per share growth next year Kintara Therapeutics Inc|oncternal.com (ONCT) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year PRTG (Portage Biotech Corp)